Sequence: e4k4-x-PLGLAG-r9-x-c
| Experiment Id | EXP001667 |
|---|---|
| Paper | Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antia |
| Peptide | dtACPP |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Dose: 50 µg DNA/mouse (tail vein); DGL:DNA 6:1 |
| Rna Concentration | 50 µg DNA/mouse |
| Mixing Ratio | DGL:DNA w/w 6:1 |
| Formulation Format | PEGylated DGL nanoparticles (peptide-PEG-DGL/DNA complexes) |
| Formulation Components | Dendrigraft poly-L-lysine (DGL G3) + MAL-PEG-NHS (PEG 3500) + dtACPP peptide; complexes with plasmid shVEGF (± DOX intercalated) |
| Size Nm | 145.00 |
| Zeta Mv | 2.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Intracranial U-87 MG glioma-bearing nude mice |
| Administration Route | Intravenous (tail vein) |
| Output Type | gene knockdown / antiangiogenesis |
| Output Value | VEGF mRNA reduced to ~34.3% of control in glioma; fewer functional/tumor-associated blood vessels |
| Output Units | |
| Output Notes | Systemic administration; RT-PCR on glioma tissue; vascular function assessed with lectin/CD34 staining |
| Toxicity Notes | Described as little side effects; improved body-weight profile vs controls |
| Curation Notes |